By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expedeon and Protein Discovery today announced that they have signed a merger agreement.

Under the terms of the deal, the new company will keep the Expedeon name and remain headquartered in Cambridge, UK. Heikki Lanckriet, founder and CEO of Expedeon, will be the CEO of the new firm. Chuck Witkowski, founder and CEO of Protein Discovery, will join Expedeon's board of directors, the firms said.

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.